Tylenol poised to reclaim top spot

NEW BRUNSWICK, N.J. — Tylenol has retaken the OTC pain relief aisle with a vengeance. The brand is close to reclaiming the top spot among internal analgesic tablets behind Aleve and Advil and is growing at a 10% rate on a dollar base of more than $250 million. “I think now we have more than 80% of our brands returned to the shelf,” Johnson & Johnson chairman and CEO Alex Gorsky said. Tylenol Arthritis will be the next pain brand being brought back, he added.

(Click here for the full Category Review.)